A pharmacodynamically guided dose selection of PF-00337210 in a phase I study in patients with advanced solid tumors

Justine Yang Bruce,Patricia LoRusso,Priscila Hermont Goncalves,Elisabeth I. Heath,Elizabeth A. Sadowski,David R. Shalinsky,Yanwei Zhang,Anne M. Traynor,Aurora Breazna,Alejandro D. Ricart,Michael A. Tortorici,Glenn Liu

A pharmacodynamically guided dose selection of PF-00337210 in a phase I study in patients with advanced solid tumors

2016

Justine Yang Bruce
Patricia LoRusso
Priscila Hermont Goncalves
Elisabeth I. Heath
Elizabeth A. Sadowski
David R. Shalinsky
Yanwei Zhang
Anne M. Traynor
Aurora Breazna
Alejandro D. Ricart
Michael A. Tortorici
Glenn Liu

Purpose PF-00337210 is an oral, highly selective vascular endothelial growth factor receptor (VEGFR) inhibitor. We evaluated a composite of biomarkers in real time to identify the recommended phase 2 dose (RP2D) and preliminary anticancer activity of PF-00337210.

Keywords:

Pharmacology
Vascular Endothelial Growth Factor Receptor
Tyrosine-kinase inhibitor
Biomarker (medicine)
VEGF receptors
Medicine
dose selection
in patient
phase i study
highly selective

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations